Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Vaccinia peptides eluted from HLA-DR1 isolated from virus-infected cells are recognized by CD4+ T cells from a vaccinated donor.

Strug I, Calvo-Calle JM, Green KM, Cruz J, Ennis FA, Evans JE, Stern LJ.

J Proteome Res. 2008 Jul;7(7):2703-11. doi: 10.1021/pr700780x. Epub 2008 May 29. Erratum in: J Proteome Res. 2009 Feb;8(2):1104.

2.

Human CD4+ T cell epitopes from vaccinia virus induced by vaccination or infection.

Calvo-Calle JM, Strug I, Nastke MD, Baker SP, Stern LJ.

PLoS Pathog. 2007 Oct 12;3(10):1511-29.

3.

Human cytotoxic CD4+ T cells recognize HLA-DR1-restricted epitopes on vaccinia virus proteins A24R and D1R conserved among poxviruses.

Mitra-Kaushik S, Cruz J, Stern LJ, Ennis FA, Terajima M.

J Immunol. 2007 Jul 15;179(2):1303-12.

4.

HLA-DM constrains epitope selection in the human CD4 T cell response to vaccinia virus by favoring the presentation of peptides with longer HLA-DM-mediated half-lives.

Yin L, Calvo-Calle JM, Dominguez-Amorocho O, Stern LJ.

J Immunol. 2012 Oct 15;189(8):3983-94. doi: 10.4049/jimmunol.1200626. Epub 2012 Sep 10.

5.

GM-CSF production allows the identification of immunoprevalent antigens recognized by human CD4+ T cells following smallpox vaccination.

Judkowski V, Bunying A, Ge F, Appel JR, Law K, Sharma A, Raja-Gabaglia C, Norori P, Santos RG, Giulianotti MA, Slifka MK, Douek DC, Graham BS, Pinilla C.

PLoS One. 2011;6(9):e24091. doi: 10.1371/journal.pone.0024091. Epub 2011 Sep 9.

6.

Discovery of naturally processed and HLA-presented class I peptides from vaccinia virus infection using mass spectrometry for vaccine development.

Johnson KL, Ovsyannikova IG, Mason CJ, Bergen HR 3rd, Poland GA.

Vaccine. 2009 Dec 10;28(1):38-47. doi: 10.1016/j.vaccine.2009.09.126. Epub 2009 Oct 12.

7.

HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation.

Oseroff C, Kos F, Bui HH, Peters B, Pasquetto V, Glenn J, Palmore T, Sidney J, Tscharke DC, Bennink JR, Southwood S, Grey HM, Yewdell JW, Sette A.

Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13980-5. Epub 2005 Sep 19.

8.

Mass tag-assisted identification of naturally processed HLA class II-presented meningococcal peptides recognized by CD4+ T lymphocytes.

Meiring HD, Kuipers B, van Gaans-van den Brink JA, Poelen MC, Timmermans H, Baart G, Brugghe H, van Schie J, Boog CJ, de Jong AP, van Els CA.

J Immunol. 2005 May 1;174(9):5636-43.

10.

Direct interrogation of viral peptides presented by the class I HLA of HIV-infected T cells.

Yaciuk JC, Skaley M, Bardet W, Schafer F, Mojsilovic D, Cate S, Stewart CJ, McMurtrey C, Jackson KW, Buchli R, Olvera A, CedeƱo S, Plana M, Mothe B, Brander C, West JT, Hildebrand WH.

J Virol. 2014 Nov;88(22):12992-3004. doi: 10.1128/JVI.01914-14. Epub 2014 Aug 27.

11.

Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes.

Johnson LE, McNeel DG.

Prostate. 2012 May 15;72(7):730-40. doi: 10.1002/pros.21477. Epub 2011 Aug 30.

PMID:
22529020
12.

Identification of novel HLA-DR1-restricted epitopes from the hepatitis B virus envelope protein in mice expressing HLA-DR1 and vaccinated human subjects.

Pajot A, Michel ML, Mancini-Bourgine M, Ungeheuer MN, Ojcius DM, Deng Q, Lemonnier FA, Lone YC.

Microbes Infect. 2006 Oct;8(12-13):2783-90. Epub 2006 Sep 12.

PMID:
17045504
13.

Virus-encoded ectopic CD74 enhances poxvirus vaccine efficacy.

Walline CC, Deffit SN, Wang N, Guindon LM, Crotzer VL, Liu J, Hollister K, Eisenlohr LC, Brutkiewicz RR, Kaplan MH, Blum JS.

Immunology. 2014 Apr;141(4):531-9. doi: 10.1111/imm.12210.

14.

Modified vaccinia virus Ankara-infected dendritic cells present CD4+ T-cell epitopes by endogenous major histocompatibility complex class II presentation pathways.

Thiele F, Tao S, Zhang Y, Muschaweckh A, Zollmann T, Protzer U, Abele R, Drexler I.

J Virol. 2015 Mar;89(5):2698-709. doi: 10.1128/JVI.03244-14. Epub 2014 Dec 17.

15.

Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA class II restricted T(H) response.

BenMohamed L, Krishnan R, Longmate J, Auge C, Low L, Primus J, Diamond DJ.

Hum Immunol. 2000 Aug;61(8):764-79.

PMID:
10980387
16.
17.

Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine.

Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J.

J Natl Cancer Inst. 1995 Jul 5;87(13):982-90.

PMID:
7629885
18.

ORFeome approach to the clonal, HLA allele-specific CD4 T-cell response to a complex pathogen in humans.

Jing L, McCaughey SM, Davies DH, Chong TM, Felgner PL, De Rosa SC, Wilson CB, Koelle DM.

J Immunol Methods. 2009 Aug 15;347(1-2):36-45. doi: 10.1016/j.jim.2009.05.011. Epub 2009 Jun 9.

19.

A reductionist cell-free major histocompatibility complex class II antigen processing system identifies immunodominant epitopes.

Hartman IZ, Kim A, Cotter RJ, Walter K, Dalai SK, Boronina T, Griffith W, Lanar DE, Schwenk R, Krzych U, Cole RN, Sadegh-Nasseri S.

Nat Med. 2010 Nov;16(11):1333-40. doi: 10.1038/nm.2248. Epub 2010 Oct 31.

20.

Long-term immunity against actual poxviral HLA ligands as identified by differential stable isotope labeling.

Meyer VS, Kastenmuller W, Gasteiger G, Franz-Wachtel M, Lamkemeyer T, Rammensee HG, Stevanovic S, Sigurdardottir D, Drexler I.

J Immunol. 2008 Nov 1;181(9):6371-83.

Supplemental Content

Support Center